title: Perforated intestinal metastasis while taking the BRAF inhibitor, vemurafanib.
authors.affiliation: General Surgery, Hutt Hospital, Wellington, New Zealand.
authors.forename: Fraser
authors.initials: F
authors.lastname: Welsh
authors.forename: Wai Keat
authors.initials: WK
authors.lastname: Chang
authors.forename: Steven
authors.initials: S
authors.lastname: Purchas
mesh_terms: D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007414:Intestinal Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000601:surgery; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery; D007421:Intestine, Small; D007813:Laparotomy; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012422:Rupture, Spontaneous; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology*; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf